We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nanovaccine Showing Potent Immunotherapy to Tumor by Activating Γδ T Cells.
- Authors
Yang, Zeyu; Li, Liyan; Wei, Chengxiu; Liu, Hong; Qiao, Dongdong; Wen, Zhenfu; Chen, Haolin; Huang, Shanghui; Guo, Rui; Yin, Zhinan; Liu, Lixin; Chen, Yongming
- Abstract
Most vaccines are designed to attack tumor cells by activating CD4+/CD8+αβ T cells. Unfortunately, αβ T cells, which only recognize the peptide antigens in the complexes with polymorphic MHCI/II molecules, surrender to the tumor heterogenicity. As another subset of T cells, γδ T cells become salient in antitumor because of their unique immunotherapeutic roles. Herein, a tumor vaccine is developed with multivalent antigens by fusion of tumor cell membranes with lipids and successfully activated γδ T cells via microneedle inoculation. It is certified that the evoked γδ T cells synchronize with αβ T cells revitalizing tumor‐induced immunotolerance. In turn, the tumors of mice are significantly inhibited and their median survival time is prolonged considerably. Moreover, the nanovaccine inhibits tumor recurrence after resection. The therapeutic effects are corroborated with the results from TCRδ−/− mice as well as cytokine expression in tumor.
- Subjects
T cells; T cell receptors; MEMBRANE fusion; CANCER vaccines; IMMUNOTHERAPY; MEMBRANE lipids; SURVIVAL rate
- Publication
Advanced Functional Materials, 2023, Vol 33, Issue 44, p1
- ISSN
1616-301X
- Publication type
Article
- DOI
10.1002/adfm.202303537